Table 10
Pooled analysis of mortality in NYHA class III and IV patients in USCP, CIBIS II, and MERIT-HF
NYHA class
Placebo (mortality)
β Blocker (mortality)
III
334/2373 (14.1%)
217/2519 (8.6%)
IV
71/313 (22.7%)
53/309 (17.5%)